Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA).

It received marketing approval in Canada and the United States.

As of 2007, it was the only GBCA approved at 1.0 molar concentrations.

Gadobutrol is marketed by Bayer AG as Gadovist, and by Bayer HealthCare Pharmaceuticals as Gadavist.

In India, it is also marketed by Vivere Imaging as Viv-butrol.